Compound · clinical trials

Doxorubicin clinical trials

Also listed in trial records as Rubex, Adriablastin, L01DB01, FI 106, C27H29NO11•HCL

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 156 trials in our China, Canada, Israel, Australia, France, Spain, USA, Italy, Germany, Mexico, South Korea, Poland, Belgium, Brazil, UK, Japan, Taiwan, Austria, Netherlands, Czechia, Denmark, Turkey, Portugal, Switzerland, Singapore, Sweden, Ireland, Norway, Egypt and India registers that name Doxorubicin as an intervention. Synced 9 Nov 2026

156Current trials

70Recruiting now

90Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Doxorubicin is named as an intervention in 156 current clinical trials in our China, Canada, Israel, Australia, France, Spain, USA, Italy, Germany, Mexico, South Korea, Poland, Belgium, Brazil, UK, Japan, Taiwan, Austria, Netherlands, Czechia, Denmark, Turkey, Portugal, Switzerland, Singapore, Sweden, Ireland, Norway, Egypt and India registers. 70 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is National Cancer Institute (NCI) (18). The most-studied condition is Breast Cancer. The EU clinical trials register (CTIS) separately lists 11 authorised or ongoing trials, 3 with a site in Ireland.

Where Doxorubicin is approved

All regulators →

Of the three regulators tracked here, the first to approve Doxorubicin was the US, on 7 Aug 1974. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

7 Aug 1974

Doxorubicin Hydrochloride

NDA050467 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

20 Jun 1996

Caelyx pegylated liposomal

EMA product page

First centralised authorisation

CACanada (Health Canada)

18 Apr 1995

Doxorubicin Hydrochloride For Injection

Notice of Compliance 4997

First new-drug NOC

7 EU orphan designations, most recently for treatment of soft-tissue sarcoma (22 May 2025, positive)

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Doxorubicin

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$2.4m

18,748 prescriptions in 2025 · Doxorubicin Hydrochloride, Doxorubicin Hydrochloride, Doxil

+11% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Doxorubicin works

All drug targets →

DNA topoisomerase II alpha inhibitor Inhibitor
Target: TOP2A DNA topoisomerase II alpha
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on TOP2A

Etoposide Daunorubicin Adriamycin Idarubicin Mitoxantrone Dexrazoxane Amrubicin Teniposide

Diseases it has been tested for in clinical trials, by furthest phase

B-cell acute lymphoblastic leukemiaPhase 3
B-cell non-Hodgkin lymphomaPhase 3
Ewing sarcomaPhase 3
Hodgkins lymphomaPhase 3
NephroblastomaPhase 3
T-cell acute lymphoblastic leukemiaPhase 3
T-cell non-Hodgkin lymphomaPhase 3
T-lymphoblastic lymphomaPhase 3
Wilms tumorPhase 3
Acute lymphoblastic leukemiaPhase 3

205 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL53463, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7069, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Doxorubicin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 6 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Caelyx pegylated liposomal, Myocet liposomal (previously Myocet), Zolsketil pegylated liposomal
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Doxorubicin

ATC code: L01DB01
ChEMBL: CHEMBL53463
DrugBank: DB00997
PubChem CID: 31703
CAS number: 23214-92-8
FDA UNII: 80168379AG
Wikidata: Q18936
Wikipedia: Doxorubicin

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting7045%
Not yet open2113%
Active, closed6340%
By invitation21%

Trials by phase

Phase 36240%
Phase 24831%
Phase 1/22214%
Phase 196%
Phase 2/374%
Phase 443%
Not applicable21%
Observational21%

Clinical trials of Doxorubicin

156 trials

Study	Phase	Status	Lead sponsor	Registers
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India NCT06831370 · Hodgkin Lymphoma	Phase 4	Recruiting	Takeda	India
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study NCT07908888 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 4	Recruiting	The First Hospital of Jilin University	China
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia NCT03150693 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Canada, Mexico, Israel
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 NCT03643276 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Recruiting	Martin Schrappe	Germany, Italy, Switzerland, Austria, Czechia, Australia, Israel
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas NCT03805022 · ClinicalTrials.gov ↗ · Non-metastatic Soft-tissue Sarcoma, Resectable	Phase 3	Recruiting	Institut Bergonié	France
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy NCT03959085 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma NCT04043494 · Lymphoblastic Lymphoma, Childhood	Phase 3	Recruiting	University Hospital Muenster	Ireland, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Israel
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035 · ClinicalTrials.gov ↗ · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Australia, Israel
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) NCT04638790 · Hodgkin Lymphoma, Adult	Phase 3	Recruiting	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	India
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma NCT04685616 · Hodgkin Lymphoma	Phase 3	Recruiting	University College, London	Ireland, Spain, Netherlands, Belgium, Denmark, Portugal, Canada, Australia
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab NCT05675410 · ClinicalTrials.gov ↗ · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8	Phase 3	Recruiting	SWOG Cancer Research Network	Mexico, Israel
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer NCT06058377 · ClinicalTrials.gov ↗ · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Israel
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254 · Follicular Lymphoma (FL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma NCT06220032 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 3	Recruiting	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer NCT06340568 · Endometrial Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) NCT06401330 · Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor	Phase 3	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas NCT06422806 · ClinicalTrials.gov ↗ · Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer NCT06584032 · ClinicalTrials.gov ↗ · Advanced Endometrial Cancer	Phase 3	Recruiting	Hutchmed	China
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma NCT06647953 · ClinicalTrials.gov ↗ · Pleuropulmonary Blastoma	Phase 3	Recruiting	Children's Oncology Group	Canada
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) NCT06717347 · Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA, China, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Hansoh BioMedical R&D Company	China
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) NCT06911502 · Follicular Lymphoma	Phase 3	Recruiting	Celgene	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Australia
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336 · Endometrial Cancer, Malignant Solid Tumour	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) NCT07286331 · Neoplasms, Endometrial	Phase 3	Recruiting	GlaxoSmithKline	UK, USA, Canada, Brazil, Japan, South Korea, Australia, Israel
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer NCT07441460 · ClinicalTrials.gov ↗ · Resectable HER2-positive Breast Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc	China
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer NCT04628767 · ClinicalTrials.gov ↗ · Renal Pelvis and Ureter Urothelial Carcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment NCT06563245 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Child, Adolescent	Phase 2/3	Recruiting	Children's Cancer Group, China	China
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients NCT04159818 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT NCT04322318 · ClinicalTrials.gov ↗ · Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor	Phase 2	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma NCT04776525 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma	Phase 2	Recruiting	Oslo University Hospital	Norway
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma NCT04922567 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma, Lenalidomide, CHOP	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia NCT06034561 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission	Phase 2	Recruiting	Instituto do Cancer do Estado de São Paulo	Brazil
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. NCT06250959 · ClinicalTrials.gov ↗ · ALL, Adult, Philadelphia-Negative ALL	Phase 2	Recruiting	Chen Suning	China
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154 · ClinicalTrials.gov ↗ · Leiomyosarcoma, Liposarcoma, Synovial Sarcoma	Phase 2	Recruiting	HRYZ Biotech Co	China
Ma-Spore ALL 2020 Study NCT06336395 · ClinicalTrials.gov ↗ · B Lymphoblastic Leukemia	Phase 2	Recruiting	National University Hospital, Singapore	Singapore
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma NCT06367075 · ClinicalTrials.gov ↗ · Advanced Soft-tissue Sarcoma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour NCT06524583 · ClinicalTrials.gov ↗ · Leiomyosarcoma Uterus	Phase 2	Recruiting	UNICANCER	France
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma NCT06704555 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL NCT06803693 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 2	Recruiting	Ruijin Hospital	China
Using Tumor Models to Determine Treatments NCT06813079 · ClinicalTrials.gov ↗ · Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor	Phase 2	Recruiting	University Health Network, Toronto	Canada
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) NCT06835049 · ClinicalTrials.gov ↗ · Sarcoma,Soft Tissue	Phase 2	Recruiting	Swiss Cancer Institute	Switzerland
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) NCT06890884 · Lymphoma, Large B-Cell, Diffuse	Phase 2	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, Italy, Belgium, Poland, Japan, Israel, Egypt
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) NCT06960577 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate	Phase 2	Recruiting	AstraZeneca	France, Spain, Italy, Netherlands, Canada, Brazil, Australia
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Ou Bai, MD/PHD	China
A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation NCT07917780 · Richter Transformation	Phase 2	Recruiting	German CLL Study Group	Ireland, Germany, Denmark, Austria, Australia
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement	Phase 1/2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma NCT04625907 · Rhabdomyosarcoma	Phase 1/2	Recruiting	University of Birmingham	Ireland, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Portugal, Australia, Israel
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma NCT05774275 · ClinicalTrials.gov ↗ · High-Risk Localized Soft Tissue Sarcoma	Phase 1/2	Recruiting	Fudan University	China
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	GI Innovation, Inc	USA, South Korea
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer NCT05981014 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1/2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Denmark, Czechia, Japan, South Korea, Taiwan, Australia
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma NCT07124936 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL)	Phase 1/2	Recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd	China
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. NCT07460986 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	MedSIR	Spain
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma NCT02811523 · ClinicalTrials.gov ↗ · Bone Sarcoma, Soft Tissue Sarcoma, Pulmonary Metastases	Phase 1	Recruiting	University Health Network, Toronto	Canada
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors NCT05785754 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	DynamiCure Biotechnology	USA, South Korea, Taiwan, Australia
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer NCT06121570 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 1	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult	Phase 1	Recruiting	NiKang Therapeutics, Inc	USA, South Korea
A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. NCT06815575 · ClinicalTrials.gov ↗ · Solid Tumours, Advanced Solid Tumours	Phase 1	Recruiting	Racura Oncology Ltd	South Korea, Australia
A Study of PHST001 in Advanced Solid Tumors NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer	Phase 1	Recruiting	Pheast Therapeutics	USA
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies NCT07308132 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin	Phase 1	Recruiting	Janssen Research & Development, LLC	France, Spain, Belgium, Turkey, Australia
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL NCT05899621 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Observational	Recruiting	Ruijin Hospital	China
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil NCT05959720 · ClinicalTrials.gov ↗ · Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality	Observational	Recruiting	Instituto do Cancer do Estado de São Paulo	Brazil
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents NCT02797717 · ClinicalTrials.gov ↗ · Classical Hodgkins Lymphoma in Children and Adolescents.	Not applicable	Recruiting	GALIA AVRAHAMI	Israel
Combination Therapy of Anthracyclines for Children With Nephroblastoma NCT03892330 · ClinicalTrials.gov ↗ · 0.5-14 Year Old Children With Nephroblastoma	Phase 4	Not yet open	Shengjing Hospital	China
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma NCT07719855 · ClinicalTrials.gov ↗ · Follicular Lymphoma ( FL)	Phase 3	Not yet open	Ruijin Hospital	China
Cardioprotection Effect of Linagliptin NCT07852546 · ClinicalTrials.gov ↗ · Cardiotoxicity	Phase 3	Not yet open	Tanta University	Egypt
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) NCT07712588 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2/3	Not yet open	Dizal Pharmaceuticals	China
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. NCT06295094 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases	Phase 2	Not yet open	Odense University Hospital	Germany, France, Sweden, Denmark
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 NCT07034508 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 2	Not yet open	Institute of Hematology & Blood Diseases Hospital, China	China
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma NCT07231250 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody	Phase 2	Not yet open	Li Zhiming	China
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial NCT07486310 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer	Phase 2	Not yet open	Guangdong Provincial People's Hospital	China
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL NCT07594899 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)	Phase 2	Not yet open	Ruijin Hospital	China
The CARDIOPROTECT Trial NCT07654426 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma	Phase 2	Not yet open	Beth Israel Deaconess Medical Center	Israel
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma NCT07677813 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 2	Not yet open	Ou Bai, MD/PHD	China
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma NCT07753642 · ClinicalTrials.gov ↗ · Nodal T-follicular Helper Cell Lymphoma	Phase 2	Not yet open	Sun Yat-sen University	China
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma NCT07802652 · ClinicalTrials.gov ↗ · Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)	Phase 2	Not yet open	Gustave Roussy, Cancer Campus, Grand Paris	France
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma NCT07842276 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin	Phase 2	Not yet open	Beijing Biostar Pharmaceuticals Co., Ltd	China
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity NCT07897409 · ClinicalTrials.gov ↗ · Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy, Doxorubicin	Phase 2	Not yet open	Universiti Sains Malaysia	Egypt
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL NCT07035379 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 1/2	Not yet open	Zhejiang Teruisi Pharmaceutical Inc	China
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients NCT07370506 · ClinicalTrials.gov ↗ · Breast Cancer, Doxorubicin Induced Cardiomyopathy	Phase 1/2	Not yet open	Tanta University	Egypt
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL NCT07638787 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma	Phase 1/2	Not yet open	Ruijin Hospital	China
Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies NCT07839819 · Advanced Solid Tumor	Phase 1/2	Not yet open	PharmaMar	USA, Germany, France, Portugal
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study NCT05287308 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Not yet open	Chinese Academy of Medical Sciences	China
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma NCT05844813 · ClinicalTrials.gov ↗ · Retroperitoneal Sarcoma	Phase 4	By invitation	Peking University International Hospital	China
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL NCT06468943 · ClinicalTrials.gov ↗ · Effects of Chemotherapy, Safety Issues	Phase 2	By invitation	The First Affiliated Hospital of Soochow University	China
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer NCT00433511 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma NCT02166463 · ClinicalTrials.gov ↗ · Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma NCT02176967 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma NCT02306161 · ClinicalTrials.gov ↗ · Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer NCT02488967 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative	Phase 3	Active, closed	NRG Oncology	Norway, Canada, Israel, Egypt
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
Paediatric Hepatic International Tumour Trial NCT03017326 · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland, Germany, France, Spain, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Israel
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents NCT03020030 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Active, closed	Dana-Farber Cancer Institute	Canada
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer NCT03595592 · ClinicalTrials.gov ↗ · Invasive Breast Cancer	Phase 3	Active, closed	Fondazione Michelangelo	Germany, Spain, Italy, Austria
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) NCT03725059 · Breast Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel, Egypt
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma NCT03907488 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia NCT03914625 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) NCT04529772 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Acerta Pharma BV	USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults NCT04530565 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586 · ClinicalTrials.gov ↗ · Primary Mediastinal Large B-Cell Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients NCT04824092 · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Incyte Corporation	Ireland, UK, USA, Germany, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer NCT05113251 · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma NCT05371093 · Relapsed/Refractory Follicular Lymphoma	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Japan
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) NCT05578976 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma NCT05605899 · High-risk Large B-cell Lymphoma (LBCL)	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Austria, Portugal, Canada, Japan, Australia
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma NCT06047080 · Large B-Cell Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) NCT06088290 · Leiomyosarcoma	Phase 3	Active, closed	PharmaMar	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma NCT06097364 · Follicular Lymphoma (FL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Turkey, Brazil, Taiwan, Australia, Israel
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) NCT06132958 · Endometrial Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma NCT06191744 · Follicular Lymphoma (FL)	Phase 3	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 NCT06284122 · Follicular Lymphoma	Phase 3	Active, closed	The Lymphoma Academic Research Organisation	Germany, France, Spain, Belgium, Switzerland, Austria, Portugal
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma NCT06356129 · Large B-cell Lymphoma	Phase 3	Active, closed	Celgene	USA, India, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) NCT06486441 · Endometrial Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature NCT02641847 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Breast Cancer	Phase 2/3	Active, closed	Fudan University	China
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma NCT03117751 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Australia
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma NCT04799275 · ClinicalTrials.gov ↗ · Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Israel
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma NCT01856192 · ClinicalTrials.gov ↗ · Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	UNICANCER	France
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma NCT03113500 · ClinicalTrials.gov ↗ · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive	Phase 2	Active, closed	City of Hope Medical Center	Canada
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma NCT03269669 · ClinicalTrials.gov ↗ · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144 · Hodgkin Lymphoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Brazil, Mexico, South Korea
9-ING-41 in Patients With Advanced Cancers NCT03678883 · Cancer, Pancreatic Cancer, Sarcoma	Phase 2	Active, closed	Actuate Therapeutics Inc	USA, France, Spain, Netherlands, Belgium, Portugal, Canada
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma NCT03712202 · ClinicalTrials.gov ↗ · Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma	Phase 2	Active, closed	City of Hope Medical Center	Israel
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients NCT04293393 · ClinicalTrials.gov ↗ · Early Breast Cancer	Phase 2	Active, closed	Spanish Breast Cancer Research Group	Spain
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma NCT04874311 · ClinicalTrials.gov ↗ · Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma	Phase 2	Active, closed	Institut Bergonié	France
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) NCT04968106 · ClinicalTrials.gov ↗ · Resectable Sarcoma	Phase 2	Active, closed	Institut Bergonié	France
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma NCT04980222 · Lymphoma	Phase 2	Active, closed	Hoffmann-La Roche	USA, France, Spain, Netherlands, Denmark, Poland
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia NCT05303792 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma	Phase 2	Active, closed	Alliance for Clinical Trials in Oncology	Mexico
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) NCT05406401 · ClinicalTrials.gov ↗ · Lymphoma, Large B-Cell, Diffuse (DLBCL)	Phase 2	Active, closed	Merck Sharp & Dohme LLC	Spain, Italy, Poland, Turkey, Canada, South Korea, Israel
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) NCT05673785 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Active, closed	Takeda	China
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) NCT06023862 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms	Phase 2	Active, closed	Yonsei University	Japan, South Korea, Taiwan, Singapore, Australia
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma NCT06425302 · Lymphoma, Follicular	Phase 2	Active, closed	Celgene	UK, USA, Germany, France, Spain, Italy, Poland, Canada, Brazil, South Korea, Taiwan, Australia
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy NCT02889523 · ClinicalTrials.gov ↗ · Lymphoma, DLBCL, Follicular Lymphoma	Phase 1/2	Active, closed	The Lymphoma Academic Research Organisation	France, Belgium
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma NCT02979522 · Hodgkin Disease	Phase 1/2	Active, closed	Takeda	USA, Italy, Brazil, Japan
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) NCT03033914 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 1/2	Active, closed	Memorial Sloan Kettering Cancer Center	Canada
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma NCT03817320 · ClinicalTrials.gov ↗ · ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood	Phase 1/2	Active, closed	Therapeutic Advances in Childhood Leukemia Consortium	Australia
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor NCT04008797 · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular	Phase 1/2	Active, closed	Eisai Inc	USA, China, France, Spain, Italy, Denmark, Canada, Japan, South Korea, Taiwan
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma NCT05201248 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Active, closed	Genmab	China
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer NCT05275777 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Solid Tumor	Phase 1/2	Active, closed	National University Hospital, Singapore	Singapore
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG NCT05615623 · ClinicalTrials.gov ↗ · Brain Tumor	Phase 1/2	Active, closed	InSightec	Canada
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) NCT05630209 · Brain Tumor	Phase 1/2	Active, closed	InSightec	USA
Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas NCT05809830 · ClinicalTrials.gov ↗ · Advanced Soft-tissue Sarcoma	Phase 1/2	Active, closed	Grupo Espanol de Investigacion en Sarcomas	Spain
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma NCT04884035 · Lymphoma, B-Cell	Phase 1	Active, closed	Celgene	USA, Spain, Poland, South Korea, Taiwan, Australia
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma NCT06251180 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma	Phase 1	Active, closed	Guangzhou Lupeng Pharmaceutical Company LTD	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Doxorubicin in the EU trials register (CTIS)

11 trials · 3 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Doxorubicin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer 2025-524202-15-00 · Neoplasms	Phase 3	Ongoing	Genmab A/S	Ireland + 11 more
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2) 2025-522748-42-00 · Neoplasms	Phase 3	Ongoing	Incyte Corp	Ireland + 7 more
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2 2024-513445-37-00 · Neoplasms	Phase 3	Ongoing	University Of Cologne	Ireland + 5 more
A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer 2025-523366-24-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Glaxosmithkline Research & Development Limited	Czechia, Poland, Austria + 9 more
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy 2025-523362-25-00 · Neoplasms	Phase 3	Authorised	Glaxosmithkline Research & Development Limited	Denmark, Netherlands, Italy + 9 more
BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma 2025-521749-26-00 · Hemic and Lymphatic Diseases	Phase 2	Authorised	University Of Cologne	Germany
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma 2026-525406-36-00 · Neoplasms	Phase 2	Authorised	Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia	Italy
COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial 2026-526122-41-00 · Not possible to specify	Phase 2	Authorised	Uppsala University Hospital	Sweden
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia 2025-522190-11-01 · Neoplasms	Phase 3	Authorised	Universitaetsklinikum Schleswig-Holstein AöR	Germany
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy 2024-519818-31-01 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Genmab A/S	Poland, Denmark, Finland + 8 more
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) 2024-518777-34-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	AstraZeneca AB	Italy, Netherlands, Lithuania + 12 more

Doxorubicin across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

6 single-substance products containing Doxorubicin on the HPRA medicines list.

Doxorubicin Rivopharm 2 mg/ml concentrate for solution for infusionRivopharm Limited · PA2318/002/001 · Marketed
Doxorubicin Teva 2 mg/ml Concentrate for Solution for InfusionTeva Pharma B.V. · PA0749/083/001 · Marketed
Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusionBaxter Holding B.V. · EU/1/96/011/001-004
Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusionCHEPLAPHARM Arzneimittel GmbH · EU/1/00/141/001
Doxorubicin 2 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/083/001 · Not marketed

All 6 Irish products →

Supply shortages

DOXO-cell 150 mg InjektionslösungGermany (BfArM) · Production problem · 16 Sep 2024 to 19 Jan 2027
DOXO-cell 50 mg InjektionslösungGermany (BfArM) · Production problem · 16 Aug 2024 to 19 Jan 2027
Doxorubicinhydrochlorid Bendalis 2 mg/mlGermany (BfArM) · Production problem · 15 Nov 2024 to 31 Dec 2026

EU shortages US shortages German shortages

Conditions studied with Doxorubicin

221 conditions

Breast Cancer6 Diffuse Large B-Cell Lymphoma6B Acute Lymphoblastic Leukemia6Endometrial Cancer5 Follicular Lymphoma5Hodgkin Lymphoma4Breast Neoplasms4 Advanced Solid Tumor4 Lymphoma4 DLBCL - Diffuse Large B Cell Lymphoma4 Follicular Lymphoma (FL)3 Large B-cell Lymphoma3

All 221 conditions

Condition (as registered)	Trials
Breast Cancer	6
Diffuse Large B-Cell Lymphoma	6
B Acute Lymphoblastic Leukemia	6
Endometrial Cancer	5
Follicular Lymphoma	5
Hodgkin Lymphoma	4
Breast Neoplasms	4
Advanced Solid Tumor	4
Lymphoma	4
DLBCL - Diffuse Large B Cell Lymphoma	4
Follicular Lymphoma (FL)	3
Large B-cell Lymphoma	3
Soft Tissue Sarcoma (STS)	3
Ovarian Cancer	3
Diffuse Large B-Cell Lymphoma (DLBCL)	3
Advanced Soft-tissue Sarcoma	3
Neuroblastoma	3
B Lymphoblastic Lymphoma	3
Diffuse Large B-cell Lymphoma (DLBCL)	2
Hepatoblastoma	2
Carcinoma, Hepatocellular	2
Lymphoblastic Lymphoma, Childhood	2
Leiomyosarcoma	2
Brain Tumor	2
Endometrial Neoplasms	2
Doxorubicin	2
DLBCL	2
Acute Lymphoblastic Leukemia	2
Mixed Phenotype Acute Leukemia	2
Acute Lymphoblastic Leukemia, Pediatric	2
Metastatic Breast Cancer	2
Soft Tissue Sarcoma	2
Ganglioneuroblastoma, Nodular	2
Anatomic Stage II Breast Cancer AJCC v8	2
Cardiotoxicity	2
Doxorubicin Induced Cardiomyopathy	2
Breast Adenocarcinoma	2
Ganglioneuroblastoma	2
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma	2
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	2
Richter Transformation	1
Lymphoma, Large B-Cell, Diffuse	1
Diffuse Large B-cell Lymphoma	1
Rhabdomyosarcoma	1
Relapsed/Refractory Follicular Lymphoma	1
High-risk Large B-cell Lymphoma (LBCL)	1
Neoplasms, Endometrial	1
Lymphoma, Follicular	1
Triple Negative Breast Neoplasms	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Chronic Lymphocytic Leukaemia	1
Small Lymphocytic Lymphoma	1
Mantle-cell Lymphoma	1
Malignant Solid Tumour	1
Large B-Cell Lymphoma	1
Advanced or Metastatic Solid Tumors	1
Metastatic Solid Tumor	1
Platinum-resistant Ovarian Cancer (PROC)	1
Solid Tumor	1
Solid Tumor, Adult	1
Metastatic Tumor	1
HER2-positive Early Breast Cancer	1
Advanced Solid Tumors	1
Cholangiocarcinoma	1
Hodgkin Disease	1
Lymphoma, B-Cell	1
Neoplasms	1
Liver Neoplasms	1
Cancer	1
Pancreatic Cancer	1
Sarcoma	1
Renal Cancer	1
Hodgkin Lymphoma, Adult	1
Advanced Gastric Cancer	1
Large B-Cell Lymphoma (LBCL)	1
ALL, Adult	1
Philadelphia-Negative ALL	1
Utidelone	1
Diffuse Large B Cell Lymphoma (DLBCL)	1
Retroperitoneal Sarcoma	1
Liposarcoma	1
Synovial Sarcoma	1
Angiosarcoma	1
B-cell Non-Hodgkin Lymphoma	1
Resectable HER2-positive Breast Cancer	1
Nodal T-follicular Helper Cell Lymphoma	1
B-Cell Non-Hodgkin Lymphoma	1
0.5-14 Year Old Children With Nephroblastoma	1
Untreated	1
MYC Gene Rearrangement	1
Follicular Lymphoma ( FL)	1
Classical Hodgkin Lymphoma	1
Child	1
Adolescent	1
Young Adult	1
Peripheral T-Cell Lymphoma	1
Lenalidomide	1
CHOP	1
Locally Advanced Thyroid Gland Carcinoma	1
Thyroid Cancer	1
High-Risk Localized Soft Tissue Sarcoma	1
Triple Negative Breast Cancer	1
Effects of Chemotherapy	1
Safety Issues	1
Chemo-free Therapy	1
Bispecific Antibody	1
Advanced Endometrial Cancer	1
Invasive Breast Cancer	1
T Acute Lymphoblastic Leukemia	1
Gastric Cancer	1
Chemotherapy, Adjuvant	1
Peritoneal Metastases	1
Minimally Invasive Surgical Procedures	1
High-Risk Neuroblastoma	1
Patient With Insufficient Response Chemoimmunotherapy	1
Metastatic Soft-tissue Sarcoma	1
Urinary Bladder Neoplasms	1
Immune Checkpoint Inhibitors	1
Methotrexate	1
Vinblastine	1
Undifferentiated Pleomorphic Sarcoma (UPS)	1
Dedifferentiated Liposarcoma (DDLPS)	1
Non-metastatic Soft-tissue Sarcoma	1
Resectable	1
Lymphoma, Non-Hodgkin	1
Leiomyosarcoma Uterus	1
Resectable Sarcoma	1
Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
Early Breast Cancer	1
Sarcoma,Soft Tissue	1
Anaplastic Kidney Wilms Tumor	1
Recurrent Kidney Wilms Tumor	1
Stage II Kidney Wilms Tumor	1
Stage III Kidney Wilms Tumor	1
Bone Sarcoma	1
Pulmonary Metastases	1
Metastatic Dedifferentiated Liposarcoma	1
Metastatic Undifferentiated Pleomorphic Sarcoma	1
Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8	1
Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8	1
Adult T-Cell Leukemia/Lymphoma	1
Anaplastic Large Cell Lymphoma, ALK-Negative	1
Anaplastic Large Cell Lymphoma, ALK-Positive	1
Angioimmunoblastic T-Cell Lymphoma	1
Metastatic Ewing Sarcoma	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Malignant Neoplasm in the Bone Marrow	1
Metastatic Malignant Neoplasm in the Lung	1
Pancreatic Ductal Carcinoma	1
Advanced Cancer	1
Epithelial Tumor	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Adult T Acute Lymphoblastic Leukemia	1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma	1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma	1
Pleuropulmonary Blastoma	1
Stage I Mixed Cell Type Kidney Wilms Tumor	1
Stage II Mixed Cell Type Kidney Wilms Tumor	1
Stage III Mixed Cell Type Kidney Wilms Tumor	1
Stage IV Mixed Cell Type Kidney Wilms Tumor	1
Acute Lymphoblastic Leukemia, in Relapse	1
Acute Lymphoblastic Leukemia With Failed Remission	1
Acute Lymphoid Leukemia	1
Minimal Residual Disease	1
Gene Abnormality	1
Chemotherapeutic Toxicity	1
Anatomic Stage I Breast Cancer AJCC v8	1
Anatomic Stage IIIA Breast Cancer AJCC v8	1
Anatomic Stage IIIB Breast Cancer AJCC v8	1
Ovarian Neoplasms	1
Uterine Cervical Neoplasms	1
Vulvar Cancer	1
Solid Tumours	1
Advanced Solid Tumours	1
B Lymphoblastic Leukemia	1
HER2-negative Breast Cancer	1
Acute Lymphoblastic Lymphoma	1
ALL, Childhood	1
Lymphoblastic Leukemia, Acute, Childhood	1
Classical Hodgkins Lymphoma in Children and Adolescents.	1
Anatomic Stage III Breast Cancer AJCC v8	1
HER2-Negative Breast Carcinoma	1
Hormone Receptor-Positive Breast Carcinoma	1
Ann Arbor Stage I Hodgkin Lymphoma	1
Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma	1
Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma	1
Ann Arbor Stage IA Hodgkin Lymphoma	1
Doxorubicin Induced Cardiotoxicity	1
Doxorubicin Adverse Reaction	1
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Progesterone Receptor Negative	1
Primary Mediastinal Large B-Cell Lymphoma	1
Central Nervous System Leukemia	1
Localized Resectable Neuroblastoma	1
Localized Unresectable Neuroblastoma	1
Down Syndrome	1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	1
Ann Arbor Stage IIB Hodgkin Lymphoma	1
Ann Arbor Stage IIIB Hodgkin Lymphoma	1
Ann Arbor Stage IVA Hodgkin Lymphoma	1
Ann Arbor Stage IVB Hodgkin Lymphoma	1
Ann Arbor Stage III Hodgkin Lymphoma	1
Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma	1
Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma	1
Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma	1
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Double-Expressor Lymphoma	1
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Grade 1 Follicular Lymphoma	1
Grade 2 Follicular Lymphoma	1
Grade 3a Follicular Lymphoma	1
Recurrent Follicular Lymphoma	1
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	1
Renal Pelvis and Ureter Urothelial Carcinoma	1
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma	1
Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma	1
Diffuse Large B-Cell Lymphoma Activated B-Cell Type	1

By country register

Register	Trials	Recruiting
Clinical trials in China	57	26
Clinical trials in Canada	51	21
Clinical trials in Israel	47	22
Clinical trials in Australia	46	23
Clinical trials in France	44	15
Clinical trials in Spain	42	15
Clinical trials in USA	38	14
Clinical trials in Italy	35	14
Clinical trials in Germany	34	12
Clinical trials in Mexico	32	11
Clinical trials in South Korea	30	13
Clinical trials in Poland	27	9
Clinical trials in Belgium	26	12
Clinical trials in Brazil	25	11
Clinical trials in UK	23	9
Clinical trials in Japan	23	7
Clinical trials in Taiwan	23	8
Clinical trials in Austria	22	9
Clinical trials in Netherlands	22	11
Clinical trials in Czechia	21	10
Clinical trials in Denmark	17	9
Clinical trials in Turkey	16	7
Clinical trials in Portugal	15	5
Clinical trials in Switzerland	15	7
Clinical trials in Singapore	12	6
Clinical trials in Sweden	11	5
Clinical trials in Ireland	10	6
Clinical trials in Norway	10	6
Clinical trials in Egypt	8	2
Clinical trials in India	8	4
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Doxorubicin trials

How many clinical trials are testing Doxorubicin?

156 current trials in our China, Canada, Israel, Australia, France, Spain, USA, Italy, Germany, Mexico, South Korea, Poland, Belgium, Brazil, UK, Japan, Taiwan, Austria, Netherlands, Czechia, Denmark, Turkey, Portugal, Switzerland, Singapore, Sweden, Ireland, Norway, Egypt and India registers name Doxorubicin (also registered as L01DB01) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Doxorubicin trials recruiting patients?

Yes. 70 of the 156 trials are recruiting: 26 with sites in China, 21 with sites in Canada, 22 with sites in Israel, 23 with sites in Australia, 15 with sites in France, 15 with sites in Spain, 14 with sites in USA, 14 with sites in Italy, 12 with sites in Germany, 11 with sites in Mexico, 13 with sites in South Korea, 9 with sites in Poland, 12 with sites in Belgium, 11 with sites in Brazil, 9 with sites in UK, 7 with sites in Japan, 8 with sites in Taiwan, 9 with sites in Austria, 11 with sites in Netherlands, 10 with sites in Czechia, 9 with sites in Denmark, 7 with sites in Turkey, 5 with sites in Portugal, 7 with sites in Switzerland, 6 with sites in Singapore, 5 with sites in Sweden, 6 with sites in Ireland, 6 with sites in Norway, 2 with sites in Egypt and 4 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Doxorubicin clinical trials?

National Cancer Institute (NCI) (18), Children's Oncology Group (8), Merck Sharp & Dohme LLC (7) and AstraZeneca (5), among 90 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Doxorubicin clinical trials in Ireland?

Yes. 10 trials in our Ireland register (ClinicalTrials.gov), and 3 trials in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Doxorubicin licensed in Ireland?

Yes. The HPRA medicines list includes 6 single-substance products containing Doxorubicin, for example Doxorubicin Rivopharm 2 mg/ml concentrate for solution for infusion (Rivopharm Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Doxorubicin shortage?

The registers we track list 3 entries for Doxorubicin: 3 German notices. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Doxorubicin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Doxorubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Doxorubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.